Interpace Biosciences (IDXG) 10-Q 10 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 06, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-24249
Entity Registrant Name	Interpace Biosciences, Inc.
Entity Central Index Key	0001054102
Entity Tax Identification Number	22-2919486
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Morris Corporate Center 1
Entity Address, Address Line Two	Building C
Entity Address, Address Line Three	300 Interpace Parkway
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	(855)
Local Phone Number	776-6419
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,161,405

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 3,791	$ 2,772
Restricted cash	250	600
Accounts receivable, net of allowance for doubtful accounts of $135 and $275, respectively	7,327	8,028
Other current assets	3,270	2,722
Total current assets	14,638	14,122
Property and equipment, net	6,930	7,349
Other intangible assets, net	9,126	11,351
Goodwill	8,433	8,433
Operating lease right of use assets, net	3,768	4,384
Other long-term assets	290	42
Total assets	43,185	45,681
Current liabilities:
Accounts payable	2,479	4,511
Accrued salary and bonus	2,442	3,161
Notes payable - related parties	7,720
Other accrued expenses	9,407	9,795
Current liabilities from discontinued operations	766	766
Total current liabilities	22,814	18,233
Contingent consideration, net of current portion	1,716	1,818
Operating lease liabilities, net of current portion	3,109	3,540
Other long-term liabilities	4,801	4,637
Total liabilities	32,440	28,228
Commitments and contingencies (Note 12)
Preferred stock, $.01 par value; 5,000,000 shares authorized,  47,000 Series B issued and outstanding	46,536	46,536
Stockholders’ deficit:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,142,507 and 4,075,257 shares issued, respectively; 4,122,843 and 4,055,593 shares outstanding, respectively	402	402
Additional paid-in capital	185,349	184,404
Accumulated deficit	(219,769)	(212,116)
Treasury stock, at cost (19,664 and 19,664 shares, respectively)	(1,773)	(1,773)
Total stockholders’ deficit	(35,791)	(29,083)
Total liabilities and stockholders’ deficit	(3,351)	(855)
Total liabilities, preferred stock and stockholders’ deficit	$ 43,185	$ 45,681

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Allowance for doubtful accounts	$ 135	$ 275
Temporary equity, par value	$ 0.01	$ 0.01
Temporary equity, shares authorized	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	4,142,507	4,075,257
Common stock, shares outstanding	4,122,843	4,055,593
Treasury stock, shares	19,664	19,664
Series B Preferred Stock [Member]
Temporary equity, shares issued	47,000	47,000
Temporary equity, shares outstanding	47,000	47,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue, net	$ 11,155	$ 5,446	$ 20,989	$ 14,504
Cost of revenue (excluding amortization of $1,112 and $1,115 for the three months and $2,224 and $2,230 for the six months, respectively)	5,800	3,850	11,116	9,963
Gross profit	5,355	1,596	9,873	4,541
Operating expenses:
Sales and marketing	2,776	1,596	5,128	4,077
Research and development	424	550	1,060	1,360
General and administrative	3,326	3,983	6,305	8,819
Transition expenses	858	124	2,111	180
Gain on DiamiR transaction	(235)		(235)
Acquisition related amortization expense	1,112	1,115	2,224	2,230
Total operating expenses	8,261	7,368	16,593	16,666
Operating loss	(2,906)	(5,772)	(6,720)	(12,125)
Interest accretion expense	(135)	(167)	(270)	(276)
Other (expense) income , net	(331)	438	(520)	485
Loss from continuing operations before tax	(3,372)	(5,501)	(7,510)	(11,916)
Provision for income taxes	16	13	31	28
Loss from continuing operations	(3,388)	(5,514)	(7,541)	(11,944)
Loss from discontinued operations, net of tax	(58)	(66)	(112)	(130)
Net loss	(3,446)	(5,580)	(7,653)	(12,074)
Less adjustment for preferred stock deemed dividend				(3,033)
Net loss attributable to common stockholders	$ (3,446)	$ (5,580)	$ (7,653)	$ (15,107)
Basic and diluted loss per share of common stock:
From continuing operations	$ (0.83)	$ (1.37)	$ (1.84)	$ (3.73)
From discontinued operations	(0.01)	(0.01)	(0.03)	(0.03)
Net loss per basic and diluted share of common stock	$ (0.84)	$ (1.38)	$ (1.87)	$ (3.76)
Weighted average number of common shares and common share equivalents outstanding:
Basic	4,102	4,033	4,095	4,018
Diluted	4,102	4,033	4,095	4,018

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Amortization	$ 1,112	$ 1,115	$ 2,224	$ 2,230

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, shares at Dec. 31, 2019	3,932	12
Beginning balance, value at Dec. 31, 2019	$ 393	$ (1,721)	$ 182,514	$ (185,665)
Common stock issued, shares	37
Common stock issued	$ 1
Restricted stock issued, shares	6
Restricted stock issued
Common stock issued through market sales, shares	80
Common stock issued through market sales	$ 8		476
Common stock issued through ESPP, shares
Common stock issued through ESPP
Treasury stock purchased, shares
Treasury stock purchased
Extinguishment of Series A Shares			(828)
Beneficial Conversion Feature in connection with Series B Issuance			2,205
Amortization of Beneficial Conversion Feature			(2,205)
Stock-based compensation expense			418
Net loss				(6,494)
Ending balance, shares at Mar. 31, 2020	4,055	12
Ending balance, value at Mar. 31, 2020	$ 402	$ (1,721)	182,580	(192,159)
Beginning balance, shares at Dec. 31, 2019	3,932	12
Beginning balance, value at Dec. 31, 2019	$ 393	$ (1,721)	182,514	(185,665)
Net loss					(12,074)
Ending balance, shares at Jun. 30, 2020	4,055	19
Ending balance, value at Jun. 30, 2020	$ 402	$ (1,770)	182,980	(197,739)	(16,127)
Beginning balance, shares at Mar. 31, 2020	4,055	12
Beginning balance, value at Mar. 31, 2020	$ 402	$ (1,721)	182,580	(192,159)
Common stock issued, shares
Common stock issued
Treasury stock purchased, shares		7
Treasury stock purchased		$ (49)
Stock-based compensation expense			400
Net loss				(5,580)	(5,580)
Ending balance, shares at Jun. 30, 2020	4,055	19
Ending balance, value at Jun. 30, 2020	$ 402	$ (1,770)	182,980	(197,739)	(16,127)
Beginning balance, shares at Dec. 31, 2020	4,075	20
Beginning balance, value at Dec. 31, 2020	$ 402	$ (1,773)	184,404	(212,116)	(29,083)
Common stock issued, shares	9
Common stock issued			108
Restricted stock issued, shares	12
Restricted stock issued
Common stock issued through market sales, shares
Common stock issued through market sales
Common stock issued through ESPP, shares	36
Common stock issued through ESPP
Treasury stock purchased, shares
Treasury stock purchased
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense			286
Net loss				(4,207)
Ending balance, shares at Mar. 31, 2021	4,132	20
Ending balance, value at Mar. 31, 2021	$ 402	$ (1,773)	184,798	(216,323)
Beginning balance, shares at Dec. 31, 2020	4,075	20
Beginning balance, value at Dec. 31, 2020	$ 402	$ (1,773)	184,404	(212,116)	(29,083)
Net loss					(7,653)
Ending balance, shares at Jun. 30, 2021	4,142	20
Ending balance, value at Jun. 30, 2021	$ 402	$ (1,773)	185,349	(219,769)	(35,791)
Beginning balance, shares at Mar. 31, 2021	4,132	20
Beginning balance, value at Mar. 31, 2021	$ 402	$ (1,773)	184,798	(216,323)
Common stock issued, shares	10
Common stock issued
Treasury stock purchased, shares
Treasury stock purchased
Stock-based compensation expense			551
Net loss				(3,446)	(3,446)
Ending balance, shares at Jun. 30, 2021	4,142	20
Ending balance, value at Jun. 30, 2021	$ 402	$ (1,773)	$ 185,349	$ (219,769)	$ (35,791)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities
Net loss	$ (7,653)	$ (12,074)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,943	2,708
Interest accretion expense	270	276
Bad debt (recovery) expense	(140)	250
Mark to market on warrants	209	(49)
Stock-based compensation	777	818
Amortization of deferred financing fees	88
Accrued interest	220
ESPP expense	60
Change in fair value of contingent consideration	(57)
Gain on DiamiR transaction	(235)
Other gains and expenses, net	(2)
Other changes in operating assets and liabilities:
Decrease in accounts receivable	841	2,849
Increase in other current assets	(548)	(788)
Decrease in accounts payable	(2,032)	(1,361)
Decrease in accrued salaries and bonus	(719)	(94)
(Decrease) increase in accrued liabilities	(802)	759
(Decrease) increase in long-term liabilities	(45)	33
Net cash used in operating activities	(6,825)	(6,673)
Cash Flows From Investing Activities
Purchase of property and equipment	(48)	(913)
Sale of property and equipment	39
Net cash used in investing activities	(9)	(913)
Cash Flows From Financing Activities
Issuance of common stock, net of expenses	108	434
Issuance of Series B preferred stock, net of expenses		19,537
Loan proceeds - related parties	7,500
Deferred financing fees	(105)
Borrowings on Line of Credit		400
Net cash provided by financing activities	7,503	20,371
Net increase in cash, cash equivalents and restricted cash	669	12,785
Cash, cash equivalents and restricted cash – beginning	3,372	2,321
Cash, cash equivalents and restricted cash – ending	$ 4,041	$ 15,106

OVERVIEW

OVERVIEW	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OVERVIEW	OVERVIEW Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs. COVID-19 pandemic The outbreak of the COVID-19 pandemic continues to impact a significant portion of the regions in which we operate. The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future. As our business operations continue to be impacted by the pandemic, we continue to monitor the situation and the guidance that is being provided by relevant federal, state and local public health authorities. We may take additional actions based upon their recommendations. However, it is possible that we may have to make further adjustments to our operating plans in reaction to developments that are beyond our control. While we do not anticipate any lab closures at this time beyond periodic, temporary work stoppages to clean and disinfect the labs, this could change in the future based upon conditions caused by the pandemic. It is also possible that we could experience supply chain shortages if the pandemic worsens and if one or more suppliers is unable to continue to provide us with supplies. For the foreseeable future, however, we do not anticipate supply chain shortages of critical supplies. We have developed and will continue to update our contingency plans in order to mitigate pandemic-related, adverse financial impacts upon our business. Transition costs To optimize the operations of laboratory operations within our pharma services, we transitioned activities from the Rutherford, NJ facility to our Morrisville, NC facility. We invested several million dollars to facilitate this relocation, including but not limited to the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes. We believe that this investment will result in a reduction in future operating costs; however, it is not certain whether we will fully realize the anticipated savings. We have also undergone several other cost-cutting initiatives and those costs are categorized as transition expenses as well.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, Interpace Pharma Solutions, Inc. and Interpace Diagnostics, LLC), and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities & Exchange Commission (“SEC”) on April 1, 2021 and as amended on April 29, 2021. The condensed Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions; and TVG, Inc. and its Commercial Services business unit which was sold on December 22, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the six-month period ended June 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021.

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	3. GOING CONCERN The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. As of June 30, 2021, the Company had cash and cash equivalents, net of restricted cash of $ 3.8 million, net accounts receivable of $ 7.3 million, total current assets, net of restricted cash of $ 14.4 million and total current liabilities of $ 22.8 million. For the six month period ended June 30, 2021, the Company had a net loss of $ 7.7 million and cash used in operating activities was $ 6.8 million. As of August 5, 2021 we had approximately $ 3.8 The Company has and may continue to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The delisting from Nasdaq of our common stock which is now quoted for trading on OTCQX and the Company’s resulting inability to use Form S-3 for offerings by it may each have an adverse impact on our ability to raise additional capital. The quotation of our common stock on OTCQX may provide significantly less liquidity than when our stock was listed on Nasdaq and we may experience greater difficulty in raising capital through the public or private sale of equity securities. In addition, the Company’s announcement on April 22, 2021 that it is considering strategic, financial and operational alternatives may have an impact on our ability to raise additional capital. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated operating cash requirements through the end of the third quarter of 2021. However, the Company’s secured promissory notes totaling $ 7.5 million are due August 31, 2021 and the Company does not currently have the cash balance necessary to repay the notes. The Company intends to address this deficiency by seeking an additional extension of the maturity date which may not be forthcoming and/or utilizing the debt or equity markets to raise sufficient funds to repay the notes. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates. Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Deferred Revenue For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract. Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full. Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations. Accounts Receivable The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer. Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases Other Current Assets Other current assets consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS June 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,261 $ 2,052 Prepaid expenses 783 625 Other 226 45 Total other current assets $ 3,270 $ 2,722 Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,102 4,033 4,095 4,018 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,102 4,033 4,095 4,018 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 747 638 747 638 Restricted stock and restricted stock units (RSUs) 373 42 373 42 Warrants 1,405 1,420 1,405 1,420 2,525 2,100 2,525 2,100 Reclassifications The Company reclassified certain prior period balances to conform to the current year presentation.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	5. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is attributable to the acquisition of our pharma services in July 2019. The carrying value of the intangible assets acquired was $ 15.6 million, with goodwill of approximately $ 8.3 million and identifiable intangible assets of approximately $ 7.3 million. In 2019, there was an adjustment to goodwill of $ 0.1 8.4 million. The net carrying value of the identifiable intangible assets from all acquisitions as of June 30, 2021 and December 31, 2020 are as follows: SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of June 30, 2021 As of December 31, 2020 Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 $ 609 $ 609 Total $ 39,251 $ 39,251 Accumulated Amortization $ (30,125 ) $ (27,900 ) Net Carrying Value $ 9,126 $ 11,351 Amortization expense was approximately $ 1.1 2.2 SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2021 2022 2023 2024 2025 $ 4,078 $ 2,155 $ 2,099 $ 873 $ 873 The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to June 30, 2021: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2020 $ 8,433 Adjustments - Balance as of June 30, 2021 $ 8,433

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	6. FAIR VALUE MEASUREMENTS Cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below: SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of June 30, 2021 Fair Value Measurements Carrying Fair As of June 30, 2021 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 2,175 $ 2,175 $ - $ - $ 2,175 Other long-term liabilities: Warrant liability (2) 230 230 - - 230 $ 2,405 $ 2,405 $ - $ - $ 2,405 As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 (1)(2) Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities In connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to June 30, 2021 is as follows: Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation Adjustment to Fair of Obligation/ Value/ December 31, 2020 Payments Accretion Conversions Exercises Mark to Market June 30, 2021 (unaudited) Asuragen $ 2,216 $ (254 ) $ 270 $ - $ (57 ) $ 2,175 Underwriters Warrants 21 - - - 209 230 $ 2,237 $ (254 ) $ 270 $ - $ 152 $ 2,405

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	7. LEASES Finance lease assets are included in fixed assets, net of accumulated depreciation. The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet June 30, 2021 December 31, 2020 (unaudited) Assets Financing lease assets Property and equipment, net $ 670 $ 597 Operating lease assets Operating lease right of use assets 3,768 4,384 Total lease assets $ 4,438 $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 117 $ 177 Operating lease liabilities Other accrued expenses 898 1,027 Total current lease liabilities $ 1,015 $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 92 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,109 3,540 Total long-term lease liabilities 3,201 3,678 Total lease liabilities $ 4,216 $ 4,882 The weighted average remaining lease term for the Company’s operating leases was 7.1 years as of June 30, 2021 and 7.1 6.0% . The Company’s operating lease expenses are recorded within “Cost of revenue” and “General and administrative expenses.” The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2021: SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES Operating Leases Financing Leases 2021 (remaining through December 31) $ 548 $ 82 2022 1,028 78 2023 629 65 2024 390 - 2025 402 - 2026 414 - Thereafter 1,510 - Total minimum lease payments 4,921 225 Less: amount of lease payments representing effects of discounting 914 16 Present value of future minimum lease payments 4,007 209 Less: current obligations under leases 898 117 Long-term lease obligations $ 3,109 $ 92 As of June 30, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 4,921 $ 548 $ 1,657 $ 792 $ 1,924 Total $ 4,921 $ 548 $ 1,657 $ 792 $ 1,924

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is no pending litigation involving the Company at this time. Due to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business. The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

ACCRUED EXPENSES AND LONG-TERM

ACCRUED EXPENSES AND LONG-TERM LIABILITIES	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND LONG-TERM LIABILITIES	9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES Other accrued expenses consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES June 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,320 $ 2,710 Upfront Medicare payment 1,174 2,066 Operating lease liability 898 1,027 All others 897 1,182 Accrued professional fees 719 854 Unclaimed property 565 565 Contingent consideration 459 398 Accrued capital expenditures 295 - Accrued pharma services invoices 293 108 Taxes payable 289 334 Accrued lab costs - diagnostics 172 161 Financing lease liability 117 177 ESPP payable 88 108 Accrued sales and marketing - diagnostics 78 51 Deferred revenue 43 54 Total other accrued expenses $ 9,407 $ 9,795 Long-term liabilities consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES June 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,454 $ 4,342 Warrant liability 230 21 Other 92 138 Deferred revenue 25 136 Total other long-term liabilities $ 4,801 $ 4,637

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	10. STOCK-BASED COMPENSATION Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2021 and 2020. SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS June 30, 2021 June 30, 2020 (unaudited) Risk-free interest rate 0.78 % 1.20 % Expected life 6.0 5.9 years Expected volatility 134.79 % 124.16 % Dividend yield - - During March 2021, the Company granted 312,500 stock options with an exercise price of $ 6.00 and 152,500 RSUs. The market value of the Company’s common stock was $ 5.00 at the grant date of these awards. The Company recognized approximately $ 0.6 million and $ 0.4 million of stock-based compensation expense during the three-month periods ended June 30, 2021 and 2020, respectively and approximately $ 0.8 million and $ 0.8 million of stock-based compensation expense during the six-month periods ended June 30, 2021 and 2020, respectively. The following table has a breakout of stock-based compensation expense by line item. SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Cost of revenue $ 52 $ 55 $ 102 $ 127 Sales and marketing 78 37 125 97 Research and development 24 30 59 69 General and administrative 397 278 551 525 Total stock compensation expense $ 551 $ 400 $ 837 $ 818

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	11. INCOME TAXES Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on loss from continuing operations and the effective tax rate for three- and six-month periods ended June 30, 2021 and 2020: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Provision for income tax $ 16 $ 13 $ 31 $ 28 Effective income tax rate (0.5 )% (0.2 )% (0.4 )% (0.2 )% Income tax expense for both the three- and six-month periods ended June 30, 2021 and 2020 was primarily due to minimum state and local taxes.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	12. SEGMENT INFORMATION We operate under one

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	13. DISCONTINUED OPERATIONS The components of liabilities classified as discontinued operations consist of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF DISCONTINUED OPERATIONS June 30, 2021 December 31, 2020 (unaudited) Accrued liabilities 766 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766 The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and six-months ended June 30, 2021 and 2020. Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Income from discontinued operations, before tax $ - $ - $ - $ - Income tax expense 58 66 112 130 Loss from discontinued operations, net of tax $ (58 ) $ (66 ) $ (112 ) $ (130 )

NOTES PAYABLE _ RELATED PARTIES

NOTES PAYABLE – RELATED PARTIES	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE – RELATED PARTIES	14. NOTES PAYABLE – RELATED PARTIES Secured Promissory Notes On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $ 3 2 Ampersand holds 28,000 4,666,666 19,000 3,166,668 39.1% 26.5% In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16). As a result, the Company considers the Notes and Security Agreement to be a related party transaction. The rate of interest on the Notes is equal to eight percent ( 8.0% On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $ 4.5 million, (ii) the Company and 1315 Capital amended the 1315 Capital Note to increase its principal amount to $ 3.0 million and (iii) the Company and Ampersand amended the Security Agreement to include the new total principal amount of the Notes of $ 7.5 million. The maturity date of the Notes remained the earlier of June 30, 2021 and the date on which all amounts become due upon the occurrence of any event of default and the interest rate remained 8% , and except with respect to their respective principal amounts, the terms of the Notes and the Security Agreement were otherwise unchanged. Through June 30, 2021, approximately $ 0.1 On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remains in full force and effect, and was not amended in connection with the amendments to the Notes. In the case of both amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications. As of June 30, 2021 the Company has incurred approximately $ 18 In connection with the Security Agreement, the Notes are secured by a first priority lien and security interest on substantially all of the assets of the Company. Additionally, if a change of control of the Company occurs (as defined in the Notes) the Company is required to make a prepayment of the Notes in an amount equal to the unpaid principal amount, all accrued and unpaid interest, and all other amounts payable under the Notes out of the net cash proceeds received by the Company from the consummation of the transactions related to such change of control. The Company may prepay the Notes in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed. The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	15. SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Disclosures of Non Cash Activities (in thousands) SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Six Months Ended June 30, 2021 2020 (unaudited) Operating Taxes accrued for repurchase of restricted shares $ - $ 49 Investing Preferred Stock Deemed Dividend $ - $ 3,033 Investment in DiamiR 248 - Accrued capital expenditures 295 - Financing Accrued financing costs $ 238 $ 314

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
EQUITY	16. EQUITY Preferred Stock Issuance: Securities Purchase and Exchange Agreement On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $ 20.0 1,000 19,000 19.0 1,000 1.0 In addition, the Company agreed to exchange $ 27.0 0.01 270 100,000 27,000 6.00 8.00 6% 34.0 A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $ 2.2 6.79 6.00 In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect.

WARRANTS

WARRANTS	6 Months Ended
	Jun. 30, 2021
Warrants and Rights Note Disclosure [Abstract]
WARRANTS	17. WARRANTS Warrants outstanding and warrant activity for the six-months ended June 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance December 31, 2020 Warrants Cancelled/ Expired Balance June 30, 2021 Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 870,214 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 65,434 1,975,934 1,404,648 - 1,404,648 The weighted average exercise price of the warrants is $ 15.97 0.9

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2021
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	18. RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020. The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements. In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	19. SUBSEQUENT EVENTS Sale of net operating losses (NOLs) In July 2021, the Company received approximately $ 0.7 8.7 Strategic Review In April 2021, we announced that we initiated a full review of a broad range of alternatives to enhance shareholder value. As part of this process, we are considering strategic, financial and operational alternatives involving the Company. Guggenheim Securities, LLC is serving as a strategic advisor in this process.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Accounting Estimates	Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.
Revenue Recognition	Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.
Deferred Revenue	Deferred Revenue For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.
Financing and Payment	Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
Costs to Obtain or Fulfill a Customer Contract	Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.
Accounts Receivable	Accounts Receivable The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.
Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases
Other Current Assets	Other Current Assets Other current assets consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS June 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,261 $ 2,052 Prepaid expenses 783 625 Other 226 45 Total other current assets $ 3,270 $ 2,722
Long-Lived Assets, including Finite-Lived Intangible Assets	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,102 4,033 4,095 4,018 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,102 4,033 4,095 4,018 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 747 638 747 638 Restricted stock and restricted stock units (RSUs) 373 42 373 42 Warrants 1,405 1,420 1,405 1,420 2,525 2,100 2,525 2,100 Reclassifications The Company reclassified certain prior period balances to conform to the current year presentation.
Reclassifications	Reclassifications The Company reclassified certain prior period balances to conform to the current year presentation.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF OTHER CURRENT ASSETS	Other current assets consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS June 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,261 $ 2,052 Prepaid expenses 783 625 Other 226 45 Total other current assets $ 3,270 $ 2,722
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE	SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,102 4,033 4,095 4,018 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,102 4,033 4,095 4,018
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 747 638 747 638 Restricted stock and restricted stock units (RSUs) 373 42 373 42 Warrants 1,405 1,420 1,405 1,420 2,525 2,100 2,525 2,100

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE	SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of June 30, 2021 As of December 31, 2020 Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 $ 609 $ 609 Total $ 39,251 $ 39,251 Accumulated Amortization $ (30,125 ) $ (27,900 ) Net Carrying Value $ 9,126 $ 11,351
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE	SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2021 2022 2023 2024 2025 $ 4,078 $ 2,155 $ 2,099 $ 873 $ 873
SCHEDULE OF GOODWILL CARRYING VALUE	The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to June 30, 2021: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2020 $ 8,433 Adjustments - Balance as of June 30, 2021 $ 8,433

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS	SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of June 30, 2021 Fair Value Measurements Carrying Fair As of June 30, 2021 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 2,175 $ 2,175 $ - $ - $ 2,175 Other long-term liabilities: Warrant liability (2) 230 230 - - 230 $ 2,405 $ 2,405 $ - $ - $ 2,405 As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 (1)(2) Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities
SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION	Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized. SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation Adjustment to Fair of Obligation/ Value/ December 31, 2020 Payments Accretion Conversions Exercises Mark to Market June 30, 2021 (unaudited) Asuragen $ 2,216 $ (254 ) $ 270 $ - $ (57 ) $ 2,175 Underwriters Warrants 21 - - - 209 230 $ 2,237 $ (254 ) $ 270 $ - $ 152 $ 2,405

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
SCHEDULE OF FINANCING AND OPERATING LEASES	The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet June 30, 2021 December 31, 2020 (unaudited) Assets Financing lease assets Property and equipment, net $ 670 $ 597 Operating lease assets Operating lease right of use assets 3,768 4,384 Total lease assets $ 4,438 $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 117 $ 177 Operating lease liabilities Other accrued expenses 898 1,027 Total current lease liabilities $ 1,015 $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 92 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,109 3,540 Total long-term lease liabilities 3,201 3,678 Total lease liabilities $ 4,216 $ 4,882
SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES	The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2021: SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES Operating Leases Financing Leases 2021 (remaining through December 31) $ 548 $ 82 2022 1,028 78 2023 629 65 2024 390 - 2025 402 - 2026 414 - Thereafter 1,510 - Total minimum lease payments 4,921 225 Less: amount of lease payments representing effects of discounting 914 16 Present value of future minimum lease payments 4,007 209 Less: current obligations under leases 898 117 Long-term lease obligations $ 3,109 $ 92
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES	As of June 30, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 4,921 $ 548 $ 1,657 $ 792 $ 1,924 Total $ 4,921 $ 548 $ 1,657 $ 792 $ 1,924

ACCRUED EXPENSES AND LONG-TER_2

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)	6 Months Ended
	Jun. 30, 2021
Payables and Accruals [Abstract]
SCHEDULE OF OTHER ACCRUED EXPENSES	Other accrued expenses consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES June 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,320 $ 2,710 Upfront Medicare payment 1,174 2,066 Operating lease liability 898 1,027 All others 897 1,182 Accrued professional fees 719 854 Unclaimed property 565 565 Contingent consideration 459 398 Accrued capital expenditures 295 - Accrued pharma services invoices 293 108 Taxes payable 289 334 Accrued lab costs - diagnostics 172 161 Financing lease liability 117 177 ESPP payable 88 108 Accrued sales and marketing - diagnostics 78 51 Deferred revenue 43 54 Total other accrued expenses $ 9,407 $ 9,795
SCHEDULE OF LONG TERM LIABILITIES	Long-term liabilities consisted of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES June 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,454 $ 4,342 Warrant liability 230 21 Other 92 138 Deferred revenue 25 136 Total other long-term liabilities $ 4,801 $ 4,637

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS	The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the six-month periods ended June 30, 2021 and 2020. SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS June 30, 2021 June 30, 2020 (unaudited) Risk-free interest rate 0.78 % 1.20 % Expected life 6.0 5.9 years Expected volatility 134.79 % 124.16 % Dividend yield - -
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE	SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Cost of revenue $ 52 $ 55 $ 102 $ 127 Sales and marketing 78 37 125 97 Research and development 24 30 59 69 General and administrative 397 278 551 525 Total stock compensation expense $ 551 $ 400 $ 837 $ 818

INCOME TAXES (Tables)

INCOME TAXES (Tables)	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Provision for income tax $ 16 $ 13 $ 31 $ 28 Effective income tax rate (0.5 )% (0.2 )% (0.4 )% (0.2 )%

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF DISCONTINUED OPERATIONS	The components of liabilities classified as discontinued operations consist of the following as of June 30, 2021 and December 31, 2020: SCHEDULE OF DISCONTINUED OPERATIONS June 30, 2021 December 31, 2020 (unaudited) Accrued liabilities 766 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766 The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and six-months ended June 30, 2021 and 2020. Three Months Ended Six Months Ended June 30, June 30, 2021 2020 2021 2020 (unaudited) (unaudited) Income from discontinued operations, before tax $ - $ - $ - $ - Income tax expense 58 66 112 130 Loss from discontinued operations, net of tax $ (58 ) $ (66 ) $ (112 ) $ (130 )

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	Supplemental Disclosures of Non Cash Activities (in thousands) SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Six Months Ended June 30, 2021 2020 (unaudited) Operating Taxes accrued for repurchase of restricted shares $ - $ 49 Investing Preferred Stock Deemed Dividend $ - $ 3,033 Investment in DiamiR 248 - Accrued capital expenditures 295 - Financing Accrued financing costs $ 238 $ 314

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2021
Warrants and Rights Note Disclosure [Abstract]
SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY	Warrants outstanding and warrant activity for the six-months ended June 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance December 31, 2020 Warrants Cancelled/ Expired Balance June 30, 2021 Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 870,214 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 65,434 1,975,934 1,404,648 - 1,404,648

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Aug. 05, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Cash and Cash Equivalents, at Carrying Value	$ 3,791		$ 3,791			$ 2,772
Accounts Receivable, after Allowance for Credit Loss, Current	7,327		7,327			8,028
Current assets	14,400		14,400
Liabilities, Current	22,814		22,814			$ 18,233
Net Income (Loss) Attributable to Parent	3,446	$ 5,580	7,653	$ 12,074
Net Cash Provided by (Used in) Operating Activities			6,825	$ 6,673
Secured Promissory Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 7,500		$ 7,500
Subsequent Event [Member]
Subsequent Event [Line Items]
Cash					$ 3,800

SCHEDULE OF OTHER CURRENT ASSET

SCHEDULE OF OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Lab supply inventory	$ 2,261	$ 2,052
Prepaid expenses	783	625
Other	226	45
Total other current assets	$ 3,270	$ 2,722

SCHEDULE OF BASIC AND DILUTED N

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Basic weighted average number of  common shares	4,102	4,033	4,095	4,018
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	4,102	4,033	4,095	4,018

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	2,525	2,100	2,525	2,100
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	747	638	747	638
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	373	42	373	42
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share	1,405	1,420	1,405	1,420

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Affiliate, Collateralized Security [Line Items]
Common stock, par value	$ 0.01	$ 0.01
Series B Preferred Stock [Member]
Affiliate, Collateralized Security [Line Items]
Number preferred stocks on converted basis	7,833,334

SCHEDULE OF IDENTIFIABLE INTANG

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	$ 39,251	$ 39,251
Finite-lived Intangible Assets, Accumulated Amortization	(30,125)	(27,900)
Finite-lived Intangible Assets, Net Carrying Value	$ 9,126	11,351
CLIA Lab [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	2 years 3 months 18 days
Finite-lived Intangible Assets, Gross	$ 609	609
Asuragen Acquisition [Member] | Thyroid [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 8,519	8,519
RedPath Acquisition [Member] | Pancreas Test [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	7 years
Finite-lived Intangible Assets, Gross	$ 16,141	16,141
RedPath Acquisition [Member] | Barrett's Test [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	9 years
Finite-lived Intangible Assets, Gross	$ 6,682	6,682
BioPharma Acquisition [Member] | Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	10 years
Finite-lived Intangible Assets, Gross	$ 1,600	1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	8 years
Finite-lived Intangible Assets, Gross	$ 5,700	$ 5,700

SCHEDULE OF FUTURE ESTIMATED AM

SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE (Details) $ in Thousands	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 4,078
2022	2,155
2023	2,099
2024	873
2025	$ 873

SCHEDULE OF GOODWILL CARRYING V

SCHEDULE OF GOODWILL CARRYING VALUE (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Balance Beginning	$ 8,433
Adjustments
Balance Ending	$ 8,433

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	Jul. 15, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Acquired Indefinite-lived Intangible Assets [Line Items]
Goodwill		$ 8,433		$ 8,433		$ 8,433
Amortization expense		$ 1,100	$ 1,100	$ 2,200	$ 2,200
BioPharma Acquisition [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 15,600
Goodwill	8,300						$ 100
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 7,300

SCHEDULE OF FINANCIAL INSTRUMEN

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details) - USD ($) $ in Thousands		Jun. 30, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	[1]	$ 230	$ 21
Fair value of liabilities		2,405	2,237
Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	[1]	230	21
Fair value of liabilities		2,405	2,237
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	[1]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	[1]
Fair value of liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	[1]	230	21
Fair value of liabilities		2,405	2,237
Asuragen [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[2]	2,175	2,216
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[2]	2,175	2,216
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[2]
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[2]
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	[2]	$ 2,175	$ 2,216
[1]	See Note 9, Accrued Expenses and Long-Term Liabilities
[2]	See Note 9, Accrued Expenses and Long-Term Liabilities

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Entity Listings [Line Items]
Beginning Balance	$ 2,237
Payments	(254)
Accretion	270
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	152
Ending Balance	2,405
Underwriter Warrants [Member]
Entity Listings [Line Items]
Beginning Balance	21
Payments
Accretion
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	209
Ending Balance	230
Asuragen [Member]
Entity Listings [Line Items]
Beginning Balance	2,216
Payments	(254)
Accretion	270
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	(57)
Ending Balance	$ 2,175

SCHEDULE OF FINANCING AND OPERA

SCHEDULE OF FINANCING AND OPERATING LEASES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$ 670	$ 597
Operating Lease, Right-of-Use Asset	3,768	4,384
[custom:TotalLeaseAssets-0]	4,438	4,981
Finance Lease, Liability, Current	117	177
Operating Lease, Liability, Current	898	1,027
Long-term Debt and Lease Obligation, Current	1,015	1,204
Finance Lease, Liability, Noncurrent	92	138
Operating Lease, Liability, Noncurrent	3,109	3,540
Long-term Debt and Lease Obligation	3,201	3,678
[custom:TotalLeaseLiabilities-0]	$ 4,216	$ 4,882

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Lessor, Lease, Description [Line Items]
Operating Leases 2021	$ 548
Operating Leases Thereafter	1,924
Operating Leases, Total minimum lease payments	4,921
Operating Leases, Less: current obligations under leases	898	$ 1,027
Financing Leases, Less: current obligations under leases	117	177
Operating Leases, Long-term lease obligations	3,109	3,540
Financing Leases, Long-term lease obligations	92	$ 138
Operating Leases [Member]
Lessor, Lease, Description [Line Items]
Operating Leases 2021	548
Operating Leases 2022	1,028
Operating Leases 2023	629
Operating Leases 2024	390
Operating Leases 2025	402
Operating Leases 2026	414
Operating Leases Thereafter	1,510
Operating Leases, Total minimum lease payments	4,921
Operating Leases, Less: amount of lease payments representing effects of discounting	914
Operating Leases, Present value of future minimum lease payments	4,007
Operating Leases, Less: current obligations under leases	898
Operating Leases, Long-term lease obligations	3,109
Financing Leases [Member]
Lessor, Lease, Description [Line Items]
Financing Leases 2021	82
Financing Leases 2022	78
Financing Leases 2023	65
Financing Leases 2024
Financing Leases 2025
Financing Leases 2026
Financing Leases Thereafter
Financing Leases,Total minimum lease payments	225
Financing Leases, Less: amount of lease payments representing effects of discounting	16
Financing Leases, Present value of future minimum lease payments	209
Financing Leases, Less: current obligations under leases	117
Financing Leases, Long-term lease obligations	$ 92

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
Operating lease obligations, Total	$ 4,921
Operating lease obligations, Less than 1 Year	548
Operating lease obligations, 1 to 3 Years	1,657
Operating lease obligations, 3 to 5 Years	792
Operating lease obligations, After 5 Years	$ 1,924

LEASES (Details Narrative)

LEASES (Details Narrative)	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	7 years 1 month 6 days	7 years 1 month 6 days
Operating Lease, Weighted Average Discount Rate, Percent	6.00%	6.00%

SCHEDULE OF OTHER ACCRUED EXPEN

SCHEDULE OF OTHER ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued royalties	$ 3,320	$ 2,710
Upfront Medicare payment	1,174	2,066
Operating lease liability	898	1,027
All others	897	1,182
Accrued professional fees	719	854
Unclaimed property	565	565
Contingent consideration	459	398
Accrued capital expenditures	295
Accrued pharma services invoices	293	108
Taxes payable	289	334
Accrued lab costs - diagnostics	172	161
Financing lease liability	117	177
ESPP payable	88	108
Accrued sales and marketing - diagnostics	78	51
Deferred revenue	43	54
Total other accrued expenses	$ 9,407	$ 9,795

SCHEDULE OF LONG TERM LIABILITI

SCHEDULE OF LONG TERM LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Uncertain tax positions	$ 4,454	$ 4,342
Warrant liability	230	21
Other	92	138
Deferred revenue	25	136
Total other long-term liabilities	$ 4,801	$ 4,637

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.78%	1.20%
Expected life	6 years	5 years 10 months 24 days
Expected volatility	134.79%	124.16%
Dividend yield

SCHEDULE OF STOCK-BASED COMPENS

SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	$ 551	$ 400	$ 837	$ 818
Cost of Sales [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	52	55	102	127
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	78	37	125	97
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	24	30	59	69
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	$ 397	$ 278	$ 551	$ 525

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			312,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 6
Stock Issued During Period, Shares, Restricted Stock Award, Gross			152,500
Shares Issued, Price Per Share	$ 5		$ 5
Share-based Payment Arrangement, Expense	$ 551	$ 400	$ 837	$ 818
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description			stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board.

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Provision for income tax	$ 16	$ 13	$ 31	$ 28
Effective income tax rate	(0.50%)	(0.20%)	(0.40%)	(0.20%)

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	6 Months Ended
	Jun. 30, 2021Integer
Segment Reporting [Abstract]
Number of segments	1

SCHEDULE OF DISCONTINUED OPERAT

SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Accrued liabilities	$ 766		$ 766		$ 766
Current liabilities from discontinued operations	766		766		766
Total liabilities	766		766		$ 766
Income from discontinued operations, before tax
Income tax expense	58	66	112	130
Loss from discontinued operations, net of tax	$ (58)	$ (66)	$ (112)	$ (130)

NOTES PAYABLE _ RELATED PARTI_2

NOTES PAYABLE – RELATED PARTIES (Details Narrative) - USD ($) $ in Thousands	May 10, 2021	Jan. 07, 2021	Jun. 30, 2021
Debt Instrument [Line Items]
Debt description		In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.
Financing fees			$ 100
Deferred financing cost			$ 18
Description of funded debt amount		The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.
Ampersand 2018 Limited Partnership [Member]
Debt Instrument [Line Items]
Interest rate		8.00%
Ampersand 2018 Limited Partnership [Member] | Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of holds shares		28,000
Number of convertible, common stock		4,666,666
Fully diluted percentage of common stock		39.10%
1315 Capital [Member] | Series B Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Number of holds shares		19,000
Number of convertible, common stock		3,166,668
Fully diluted percentage of common stock		26.50%
Security Agreement [Member]
Debt Instrument [Line Items]
Promissory note	$ 7,500
Interest rate	8.00%
Debt Instrument, Maturity Date	Jun. 30, 2021
Security Agreement [Member] | Ampersand 2018 Limited Partnership [Member]
Debt Instrument [Line Items]
Promissory note	$ 4,500	$ 3,000
Security Agreement [Member] | 1315 Capital [Member]
Debt Instrument [Line Items]
Promissory note	$ 3,000	$ 2,000

SCHEDULE OF SUPPLEMENTAL DISCLO

SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Taxes accrued for repurchase of restricted shares		$ 49
Preferred Stock Deemed Dividend		3,033
Investment in DiamiR	248
Accrued capital expenditures	295
Accrued financing costs	$ 238	$ 314

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	Jan. 15, 2020	Jan. 10, 2020	Jun. 30, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Preferred stock dividend percentage			6.00%
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock adjusted conversion	$ 6
Company achieve revenue target				$ 34
Intrinsic value of beneficial conversion feature	$ 2.2
Intrinsic value of effective conversion price per share	$ 6.79
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued			27,000
Preferred stock adjusted conversion			$ 6
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued			270
Value of preferred stock exchanged			$ 27
Preferred stock par/stated value			$ 0.01
Preferred shares stated value			100,000
Preferred stock adjusted conversion			$ 8
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 20
Issuance price of preferred stock		$ 1,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 19
Aggregate of shares issued		19,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand 2018 Limited Partnership [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 1
Aggregate of shares issued		1,000

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Warrants Issued	1,975,934
Warrants	1,404,648	1,404,648
Warrants Cancelled/Expired
Private Placement Warrants[Member]
Class of Warrant or Right [Line Items]
Description	Private Placement Warrants, issued January 25, 2017
Classification	Equity
Exercise Price	$ 46.90
Expiration Date	June 2022
Warrants Issued	85,500
Warrants	85,500	85,500
RedPath Warrants [Member]
Class of Warrant or Right [Line Items]
Description	RedPath Warrants, issued March 22, 2017
Classification	Equity
Exercise Price	$ 46.90
Expiration Date	September 2022
Warrants Issued	10,000
Warrants	10,000	10,000
Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Description	Underwriters Warrants, issued June 21, 2017
Classification	Liability
Exercise Price	$ 13.20
Expiration Date	December 2022
Warrants Issued	57,500
Warrants	53,500	53,500
Base & Overallotment Warrants [Member]
Class of Warrant or Right [Line Items]
Description	Base & Overallotment Warrants, issued June 21, 2017
Classification	Equity
Exercise Price	$ 12.50
Expiration Date	June 2022
Warrants Issued	1,437,500
Warrants	870,214	870,214
Warrants Issued [Member]
Class of Warrant or Right [Line Items]
Description	Warrants issued October 12, 2017
Classification	Equity
Exercise Price	$ 18
Expiration Date	April 2022
Warrants Issued	320,000
Warrants	320,000	320,000
Underwriters Warrants [Member]
Class of Warrant or Right [Line Items]
Description	Underwriters Warrants, issued January 25, 2019
Classification	Equity
Exercise Price	$ 9.40
Expiration Date	January 2022
Warrants Issued	65,434
Warrants	65,434	65,434

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member]	6 Months Ended
	Jun. 30, 2021$ / shares
Class of Warrant or Right [Line Items]
Weighted average exercise price	$ 15.97
Weighted average remaining contractual life	10 months 24 days

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)
Subsequent Event [Line Items]
Proceeds from sale of operating loss	$ 0.7
Sale of net operating loss	$ 8.7